Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of varoglutamstat (PQ912) in mild cognitive impairment and mild dementia due to Alzheimer's disease
2019-003532-23Phase 2Completed
- Sponsor
- Vivoryon Therapeutics N.V.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Varoglutamstat arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability outcomes. Started Mar 2020; status: completed.
02
Drugs
varoglutamstat
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2019-003532-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003532-23.